<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102554">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960660</url>
  </required_header>
  <id_info>
    <org_study_id>12.0216</org_study_id>
    <secondary_id>12-03-001</secondary_id>
    <nct_id>NCT01960660</nct_id>
  </id_info>
  <brief_title>A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products</brief_title>
  <official_title>A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutrasource Diagnostics Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Naturals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nutrasource Diagnostics Inc.</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supplementation with omega-3 fatty acids has been extensively researched and is known to
      provide healthful benefits for patients with a diversity of conditions and diseases.  Not
      all omega-3 supplements are created equally however; some sources of omega-3 fatty acids are
      superior to others due to a greater bioavailability of omega-3 fatty acids than others,
      differences in source material, and processing techniques.

      The purpose of this study is to determine which marketed omega-3 product provided the
      greatest effect, as measured against its' label claim and recommended dosage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Omega-Score</measure>
    <time_frame>Change from Baseline in Omega-Score at 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Omega ScoreTM is a measurement of the levels of the Omega-3 Fatty Acids in a blood sample. The summed amounts of these Omega-3 Fatty Acids (EPA+DPA+DHA) as a % of the total fatty acids represents the Omega ScoreTM in whole blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipemic IndexTM</measure>
    <time_frame>Change from Baseline in Lipemic Index at 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Lipemic Indexâ„¢ is the post-prandial rise in TG levels over a 5-hour period, following the consumption drink containing a measured amount of fat, carbohydrate and protein.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Comparative Bioavailability</condition>
  <arm_group>
    <arm_group_label>Investigational Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega-3 fatty acids in the form of triglycerides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Product 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids in the form of ethyl esters.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Product 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids in the form of phospholipids from krill oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Product 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omega-3 fatty acids from salmon oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 Fatty Acids</intervention_name>
    <arm_group_label>Investigational Product</arm_group_label>
    <arm_group_label>Comparator Product 1</arm_group_label>
    <arm_group_label>Comparator Product 2</arm_group_label>
    <arm_group_label>Comparator Product 3</arm_group_label>
    <other_name>EPA: Eicosapentaenoic acid (20:5(n-3))</other_name>
    <other_name>DHA: Docosahexaenoic acid (22:6(n-3))</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is fluent in English

          -  Participant understands the study requirements and is willing to comply with the
             protocol

          -  Participant is willing to provide written informed consent

          -  Participant is 18 years of age or older

        Exclusion Criteria:

          -  Unwilling or unable to provide written consent

          -  Participant has taken omega-3 supplements in the last 3 months

          -  Participants consumes fish on a regular basis (more than 1 serving per week)

          -  Females who are pregnant or breastfeeding

          -  Participant has an allergy to fish or seafood

          -  Participant has been diagnosed with any medical illness or conditions

          -  Participant has a history of drug dependence or substance abuse (excluding nicotine)

          -  Participant is taking cholesterol or triglyceride lowering medications or supplements
             (statins, niacin, carnitine, fibrates)

          -  Individual has difficulty giving multiple blood samples
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie D Laidlaw, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrasource Diagnostics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carla Cockerline, M.Sc</last_name>
    <role>Study Director</role>
    <affiliation>Nutrasource Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nutrasource Diagnostics Inc</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1G0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>October 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fish Oil</keyword>
  <keyword>EPA</keyword>
  <keyword>DHA</keyword>
  <keyword>Omega-Score</keyword>
  <keyword>Lipemic Index</keyword>
  <keyword>ethyl esters</keyword>
  <keyword>triglycerides</keyword>
  <keyword>phospholipids</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
